Biodexa Pharmaceuticals Plc ADR (BDRX)

$6.02 +0.09 (1.52%)
Market Cap 3.67M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 60,300
Avg Vol 83,521
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 78%
Beta 0.87
Analysts Sell
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
MomentumSpotter_
MomentumSpotter_ Sep. 12 at 9:42 PM
$NIVF $BDRX $VELO $CHPT |
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 12 at 3:53 PM
$BDRX moving her gingerly @ this second all morning due to SUGP grid has crossed into ours need to untangle this
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 12 at 3:52 PM
$BDRX need to b very very very careful with this sugp cross grid new shares entering the float causing severe issues lowr channel as we overlap dont want us caught
0 · Reply
Metal_Health
Metal_Health Sep. 12 at 2:48 PM
$BDRX aka the $QMMM of biotech 144 share float and no one on it.
0 · Reply
dbr_island
dbr_island Sep. 12 at 12:33 PM
$COCP could be a MONSTER 🏆 As you can see below NO ONE can decipher news and LOAD accordingly better than me 🏆✅ ALL profits going into INVZ 🚢📦📦📦📦📦🚨 HERE IS WHY👇 $TONX $OPI $BDRX $BHAT what a day
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 12 at 12:32 PM
$BDRX !
3 · Reply
PS600REVX
PS600REVX Sep. 11 at 5:06 PM
$BDRX in
0 · Reply
Surfude
Surfude Sep. 11 at 4:57 PM
$BDRX Come on baby! All we need is a little push!
0 · Reply
Surfude
Surfude Sep. 11 at 3:47 PM
$BDRX This will take very little vol to get it going.
0 · Reply
Metal_Health
Metal_Health Sep. 11 at 2:43 PM
$BDRX up 19% YTD on the DAX (German stock index) down 94% on Nasdaq that alone is one hell of a market anomaly. Market cap $3.5 MILLION. Untapped FAP arena $7.3 BILLION. Wait until the entities blowing up and blowing out shorts in all kinds of random low floaters find this the lowest float (144 shares) of them all. $100=$300 like $QMMM with multiple halts is possible. $30/shr cash so the float will stay that way right up until Ph3 results. A strong pipeline but #eRapa is by far their biggest. https://biodexapharma.com/pipeline/ 💎💎
0 · Reply
Latest News on BDRX
Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 1 day ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 5 days ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 26 days ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 6 weeks ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 6 weeks ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 2 months ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 2 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 2 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 2 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 2 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 3 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 3 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 3 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 3 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 4 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 4 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 4 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 5 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 5 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 6 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 6 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 6 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 7 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 7 months ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 7 months ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 7 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 8 months ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 10 months ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 10 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 11 months ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 17, 2024, 7:30 AM EDT - 11 months ago

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Oct 15, 2024, 4:15 PM EDT - 11 months ago

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Interim results for the six months ended June 30, 2024

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Interim results for the six months ended June 30, 2024

MomentumSpotter_
MomentumSpotter_ Sep. 12 at 9:42 PM
$NIVF $BDRX $VELO $CHPT |
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 12 at 3:53 PM
$BDRX moving her gingerly @ this second all morning due to SUGP grid has crossed into ours need to untangle this
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 12 at 3:52 PM
$BDRX need to b very very very careful with this sugp cross grid new shares entering the float causing severe issues lowr channel as we overlap dont want us caught
0 · Reply
Metal_Health
Metal_Health Sep. 12 at 2:48 PM
$BDRX aka the $QMMM of biotech 144 share float and no one on it.
0 · Reply
dbr_island
dbr_island Sep. 12 at 12:33 PM
$COCP could be a MONSTER 🏆 As you can see below NO ONE can decipher news and LOAD accordingly better than me 🏆✅ ALL profits going into INVZ 🚢📦📦📦📦📦🚨 HERE IS WHY👇 $TONX $OPI $BDRX $BHAT what a day
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 12 at 12:32 PM
$BDRX !
3 · Reply
PS600REVX
PS600REVX Sep. 11 at 5:06 PM
$BDRX in
0 · Reply
Surfude
Surfude Sep. 11 at 4:57 PM
$BDRX Come on baby! All we need is a little push!
0 · Reply
Surfude
Surfude Sep. 11 at 3:47 PM
$BDRX This will take very little vol to get it going.
0 · Reply
Metal_Health
Metal_Health Sep. 11 at 2:43 PM
$BDRX up 19% YTD on the DAX (German stock index) down 94% on Nasdaq that alone is one hell of a market anomaly. Market cap $3.5 MILLION. Untapped FAP arena $7.3 BILLION. Wait until the entities blowing up and blowing out shorts in all kinds of random low floaters find this the lowest float (144 shares) of them all. $100=$300 like $QMMM with multiple halts is possible. $30/shr cash so the float will stay that way right up until Ph3 results. A strong pipeline but #eRapa is by far their biggest. https://biodexapharma.com/pipeline/ 💎💎
0 · Reply
ABurgess_1998
ABurgess_1998 Sep. 11 at 2:04 PM
$BDRX NXXT supply zones get eaten fast demand imbalance suggests breakout pressure building beneath surface ahead of next print
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 1:59 PM
$BDRX absorbing $SLXN
1 · Reply
jags2255
jags2255 Sep. 11 at 1:51 PM
$BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 1:23 PM
$SLXN coding for beud $BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 1:19 PM
$SLXN u belong to me n beud ! $BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 1:19 PM
$BDRX will not give u a pump n dump SLXN i gave your move away for this reason !
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 1:18 PM
$SLS bringing SLXN down also $BDRX beud !
0 · Reply
Vulnerable
Vulnerable Sep. 11 at 12:10 PM
$BDRX $PSTV $SLS $AKBA @Love_To_Learn @Mackie2020 @cb5000calls ever notice how mo can change destiny by hopping tracks, rescue stocks, take 100 other stocks prisoners (lower) to keep a stock a price he's tagging safe, (aka always trending a little lower), but he can NEVER allow a pop in one of this stocks and SAVE it from a higher level, only from the lower level. LOLOLOZLOZLOZLOZ. Comical
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 11:27 AM
$BDRX segmented your board off 19-22 28 pt slxn used n the 34-36 38* 41-44 broken 51-pt they were vying for SLXN !
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 11:19 AM
$BDRX for SLXN* OK wont tag them its better later
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 11:11 AM
$BDRX u r needed for markets n this move slxn given from u allows that because this move they took does not have a proper long for u that they took blessings later
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 11 at 11:09 AM
$BDRX gave this sequence of your love to slxn u might feel shafted but it was for good reason… won’t tag this to them
0 · Reply